Interleukin-6 implication in prostate cancer;Implication de l'interleukine 6 dans le cancer de la prostate

Bulletin du Cancer

Volumn 94, Issue 6 SUPPL., 2007, Pages

  Cabrespine, Aurélie ^a   Bay, Jacques Olivier ^a,b   Verrelle, Pierre ^b   Morel, Laurent ^c  

^a HÔTEL DIEU   (France)

^b CENTRE JEAN PERRIN   (France)

^c UNIVERSITÉ CLERMONT AUVERGNE   (France)

Author keywords

Angiogenesis; Apoptosis; Hormone resistance; Interleukin 6; Neuroendocrine differentiation; Prostate cancer

Indexed keywords

ANDROGEN RECEPTOR; INTERLEUKIN 6;

ANGIOGENESIS; APOPTOSIS; CANCER GROWTH; CHEMOSENSITIVITY; HUMAN; NEUROENDOCRINE SYSTEM; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; TISSUE DIFFERENTIATION;

APOPTOSIS; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; HUMANS; INTERLEUKIN-6; MALE; MITOGEN-ACTIVATED PROTEIN KINASES; NEOPLASM PROTEINS; NEUROSECRETORY SYSTEMS; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, ANDROGEN; RECEPTORS, INTERLEUKIN-6; STAT3 TRANSCRIPTION FACTOR;

EID: 34547807733     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2007.0245     Document Type: Review

References (57)

1. Hill C, Doyon F. The frequency of cancer in France in year 2000, and trends since 1950. Bull Cancer 2005 ; 92 : 7-11.
2. Huggins C, Hodges CV. Studies of prostatic cancer, effect of castration, of oestrogen and of androgen on serum phosphatase in metastatic carcinoma of the prostate. Cancer Res 1941 ; 1 : 293-7.
3. Lu C, Sheehan C, Rak JW, Chambers CA, Hozumi N, Kerbel RS. Endogenous interleukin 6 can function as an in vivo growth- stimulatory factor for advanced-stage human melanoma cells. Clin Cancer Res 1996 ; 2 : 1417-25.
4. Mizutani Y, Bonavida B, Koishihara Y, Akamatsu K, Ohsugi Y, Yoshida O. Sensitization of human renal cell carcinoma cells to cis- diamminedichloroplatinum (II) by anti-interleukin 6 monoclonal antibody or anti-interleukin 6 receptor monoclonal antibody. Cancer Res 1995 ; 55 : 590-6.
5. Miyamoto Y, Hosotani R, Doi R, Wada M, Ida J, Tsuji S, et al. Interleukin-6 inhibits radiation induced apoptosis in pancreatic cancer cells. Anticancer Res 2001 ; 21 : 2449-56.
6. Hirano T, Kishimoto T. Molecular biology and immunology of interleukin-6. Res Immunol 1992 ; 143 : 723-4.
7. Raber J, O'Shea RD, Bloom FE, Campbell IL. Modulation of hypothalamic-pituitary-adrenal function by transgenic expression of interleukin-6 in the CNS of mice. J Neurosci 1997 ; 17 : 9473-80.
8. Van Snick J. Interleukin-6 : an overview. Annu Rev Immunol 1990 ; 8 : 253-78.
9. Novick D, Engelmann H, Wallach D, Rubinstein M. Soluble cytokine receptors are present in normal human urine. J Exp Med 1989 ; 170 : 1409-14.
10. Honda M, Yamamoto S, Cheng M, Yasukawa K, Suzuki H, Saito T, et al. Human soluble IL-6 receptor : its detection and enhanced release by HIV infection. J Immunol 1992 ; 1 ; 148 : 2175-80.
11. Muller-Newen G, Kuster A, Hemmann U, Keul R, Horsten U, Martens A, et al. Soluble IL-6 receptor potentiates the antagonistic activity of soluble gp130 on IL-6 responses. J Immunol 1998 ; 161 : 6347-55.
12. Peters M, Meyer zum Buschenfelde KH, Rose-John S. The function of the soluble IL-6 receptor in vivo. Immunol Lett 1996 ; 54 : 177-84.
13. Jones SA, Horiuchi S, Topley N, Yamamoto N, Fuller GM. The soluble interleukin 6 receptor : mechanisms of production and implications in disease. FASEB J 2001 ; 15 : 43-58.
14. Ward LD, Howlett GJ, Discolo G, Yasukawa K, Hammacher A, Moritz RL, et al. High affinity interleukin-6 receptor is a hexameric complex consisting of two molecules each of interleukin-6, interleukin-6 receptor, and gp-130. J Biol Chem 1994 ; 269 : 23286-9.
15. Labrie F. Androgen blockade in prostate cancer in 2002 : major benefits on survival in localized disease. Mol Cell Endocrinol 2002 ; 198 : 77-87.
16. Harris KA, Reese DM. Treatment options in hormone-refractory prostate cancer : current and future approaches. Drugs 2001 ; 61 : 2177-92.
17. Goodin S, Rao KV, DiPaola RS. State-of-the-art treatment of metastatic hormone-refractory prostate cancer. Oncologist 2002 ; 7 : 360-70.
18. Cabrespine A, Guy L, Chollet P, Debiton E, Bay JO. Molecular mechanisms involved in hormone resistance of prostate cancer. Bull Cancer 2004 ; 91 : 747-57.
19. Hobisch A, Rogatsch H, Hittmair A, Fuchs D, Bartsch G, Klocker H, et al. Immunohistochemical localization of interleukin-6 and its receptor in benign, premalignant and malignant prostate tissue. J Pathol 2000 ; 191 : 239-44.
20. Siegall CB, Schwab G, Nordan RP, FitzGerald DJ, Pastan I. Expression of the interleukin 6 receptor and interleukin 6 in prostate carcinoma cells. Cancer Res 1990 ; 50 : 7786-8.
21. Hobisch A, Eder IE, Putz T, Horninger W, Bartsch G, Klocker H, et al. Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. Cancer Res 1998 ; 58 : 4640-5.
22. Chung TD, Yu JJ, Spiotto MT, Bartkowski M, Simons JW. Characterization of the role of IL-6 in the progression of prostate cancer. Prostate 1999 ; 38 : 199-207.
23. Siegsmund MJ, Yamazaki H, Pastan I. Interleukin 6 receptor mRNA in prostate carcinomas and benign prostate hyperplasia. J Urol 1994 ; 151 : 1396-9.
24. Giri D, Ozen M, Ittmann M. Interleukin-6 is an autocrine growth factor in human prostate cancer. Am J Pathol 2001 ; 159 : 2159-65.
25. Drachenberg DE, Elgamal AA, Rowbotham R, Peterson M, Murphy GP. Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer. Prostate 1999 ; 41 : 127-33.
26. Michalaki V, Syrigos K, Charles P, Waxman J. Serum levels of IL-6 and TNF-alpha correlate with clinicopathological features and patient survival in patients with prostate cancer. Br J Cancer 2004 ; 90 : 2312-6.
27. Akimoto S, Okumura A, Fuse H. Relationship between serum levels of interleukin-6, tumor necrosis factor-alpha and bone turnover markers in prostate cancer patients. Endocr J 1998 ; 45 : 183-9.
28. Twillie DA, Eisenberger MA, Carducci MA, Hseih WS, Kim WY, Simons JW. Interleukin-6 : a candidate mediator of human prostate cancer morbidity. Urology 1995 ; 45 : 542-9.
29. Shariat SF, Andrews B, Kattan MW, Kim J, Wheeler TM, Slawin KM. Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis. Urology 2001 ; 58 : 1008-15.
30. Nakashima J, Tachibana M, Horiguchi Y, Oya M, Ohigashi T, Asakura H, et al. Serum interleukin 6 as a prognostic factor in patients with prostate cancer. Clin Cancer Res 2000 ; 6 : 2702-6.
31. George DJ, Halabi S, Shepard TF, Sanford B, Vogelzang NJ, Small EJ, et al. The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer : results from cancer and leukemia group B 9480. Clin Cancer Res 2005 ; 11 : 1815-20.
32. Tan D, Wu X, Hou M, Lee SO, Lou W, Wang J, et al. Interleukin-6 polymorphism is associated with more aggressive prostate cancer. J Urol 2005 ; 174 : 753-6.
33. Vallières L, Rivest S. L'interleukine-6 dans le système nerveux central. Med Sci (Paris) 2000 ; 16 : 936-44.
34. Chen CD, Sawyers CL. NF-kappa B activates prostate-specific antigen expression and is upregulated in androgen-independent prostate cancer. Mol Cell Biol 2002 ; 22 : 2862-70.
35. Nishimura K, Nonomura N, Satoh E, Harada Y, Nakayama M, Tokizane T, et al. Potential mechanism for the effects of dexamethasone on growth of androgen-independent prostate cancer. J Natl Cancer Inst 2001 ; 93 : 1739-46.
36. Degeorges A, Tatoud R, Fauvel-Lafeve F, Podgorniak MP, Millot G, de Cremoux P, et al. Stromal cells from human benign prostate hyperplasia produce a growth-inhibitory factor for LNCaP prostate cancer cells, identified as interleukin-6. Int J Cancer 1996 ; 68 : 207-14.
37. Okamoto M, Lee C, Oyasu R. Autocrine effect of androgen on proliferation of an androgen responsive prostatic carcinoma cell line, LNCAP : role of interleukin-6. Endocrinology 1997 ; 138 : 5071-4.
38. Mori S, Murakami-Mori K, Bonavida B. Interleukin-6 induces G1 arrest through induction of p27 (Kip1), a cyclin-dependent kinase inhibitor, and neuron-like morphology in LNCaP prostate tumor cells. Biochem Biophys Res Commun 1999 ; 257 : 609-14.
39. Spiotto MT, Chung TD. STAT3 mediates IL-6-induced growth inhibition in the human prostate cancer cell line LNCaP. Prostate 2000 ; 42 : 88-98.
40. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004 ; 10 : 33-9.
41. Ueda T, Bruchovsky N, Sadar MD. Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways. J Biol Chem 2002 ; 277 : 7076-85.
42. Culig Z, Bartsch G, Hobisch A. Interleukin-6 regulates androgen receptor activity and prostate cancer cell growth. Mol Cell Endocrinol 2002 ; 197 : 231-8.
43. Lee SO, Lou W, Hou M, de Miguel F, Gerber L, Gao AC. Interleukin-6 promotes androgen-independent growth in LNCaP human prostate cancer cells. Clin Cancer Res 2003 ; 9 : 370-6.
44. Chung TD, Yu JJ, Kong TA, Spiotto MT, Lin JM. Interleukin-6 activates phosphatidylinositol-3 kinase, which inhibits apoptosis in human prostate cancer cell lines. Prostate 2000 ; 42 : 1-7.
45. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001 ; 1 : 34-45.
46. Stratton MS, Sirvent H, Udayakumar TS, Nagle RB, Bowden GT. Expression of the matrix metalloproteinase promatrilysin in coculture of prostate carcinoma cell lines. Prostate 2001 ; 48 : 206-9.
47. Steiner H, Berger AP, Godoy-Tundidor S, Bjartell A, Lilja H, Bartsch G, et al. An autocrine loop for vascular endothelial growth factor is established in prostate cancer cells generated after prolonged treatment with interleukin 6. Eur J Cancer 2004 ; 40 : 1066-72.
48. di Sant'Agnese PA. Neuroendocrine differentiation in prostatic carcinoma : an update on recent developments. Ann Oncol 2001 ; 12 (Suppl 2) : S135-40.
49. Deeble PD, Murphy DJ, Parsons SJ, Cox ME. Interleukin-6- and cyclic AMP-mediated signaling potentiates neuroendocrine differentiation of LNCaP prostate tumor cells. Mol Cell Biol 2001 ; 21 : 8471-82.
50. Ito T, Yamamoto S, Ohno Y, Namiki K, Aizawa T, Akiyama A, et al. Up-regulation of neuroendocrine differentiation in prostate cancer after androgen deprivation therapy, degree and androgen independence. Oncol Rep 2001 ; 8 : 1221-4.
51. Lee LF, Guan J, Qiu Y, Kung HJ. Neuropeptide-induced androgen independence in prostate cancer cells : roles of nonreceptor tyrosine kinases Etk/Bmx, Src, and focal adhesion kinase. Mol Cell Biol 2001 ; 21 : 8385-97.
52. Wang Q, Horiatis D, Pinski J. Interleukin-6 inhibits the growth of prostate cancer xenografts in mice by the process of neuroendocrine differentiation. Int J Cancer 2004 ; 111 : 508-13.
53. Borsellino N, Belldegrun A, Bonavida B. Endogenous interleukin 6 is a resistance factor for cis-diamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines. Cancer Res 1995 ; 55 : 4633-9.
54. Smith PC, Keller ET. Anti-interleukin-6 monoclonal antibody induces regression of human prostate cancer xenografts in nude mice. Prostate 2001 ; 48 : 47-53.
55. Epenetos AA, Deonarain M, Wright M. High affinity anti IL-6 antibodies for the treatment of prostate cancer. Proceeding ASCO, 2005 (abstract 4803).
56. Leng Q, Mixson AJ. Small interfering RNA targeting Raf-1 inhibits tumor growth in vitro and in vivo. Cancer Gene Ther 2005 ; 12 : 682-90.
57. Ling X, Arlinghaus RB. Knockdown of STAT3 expression by RNA interference inhibits the induction of breast tumors in immunocompetent mice. Cancer Res 2005 ; 65 : 2532-6.